To evaluate the pharmacology, pharmacokinetics, clinical efficacy, safety, dosing, cost, and clinical implications of enfortumab vedotin-ejfv (EV) in the treatment of locally advanced or metastatic urothelial carcinoma (UC).
Data Sources:
A literature search of PubMed (inception to August 2020) was conducted using the terms enfortumab, vedotin, Padcev, and Nectin. Data were also obtained from package inserts, meeting abstracts, and ongoing studies from ClinicalTrials.gov.
Study Selection and Data Extraction:
All relevant published articles, package inserts, and meeting abstracts evaluating EV for the treatment of UC were analyzed.
Data Synthesis:
Antibody-drug conjugates (ADCs) deliver potent cytotoxic agents using highly selective monoclonal antibodies. Targeting the near-universal expression of Nectin-4 on UC cells is a viable therapeutic strategy. In a pivotal phase II trial, EV demonstrated an overall response rate of 44%, and a median duration of response of 7.6 months. Estimated overall survival was 11.7 months with a median estimated progression-free survival of 5.6 months. Results were similar among difficult-to-treat patients, including those with liver metastases. Unique toxicity concerns with EV require careful consideration and monitoring.
Relevance to Patient Care and Clinical Practice:
EV, a first-in-class anti–Nectin-4 ADC, provides impressive response rates with manageable toxicities, making it a promising treatment option for patients with multiply relapsed or refractory UC.
Conclusion:
The US Food and Drug Administration–approved EV demonstrates antitumor activity in heavily pretreated patients with UC but harbors important adverse effects and financial concerns. Additional studies are required to identify the optimal sequencing, patient population, and place in therapy for EV.
PowlesTDuránIvan der HeijdenMS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748-757. doi:10.1016/S0140-6736(17)33297-X
5.
PatelMREllertonJInfanteJR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19:51-64. doi:10.1016/S1470-2045(17)30900-2
6.
PowlesTO’DonnellPHMassardC, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3:e172411. doi:10.1001/jamaoncol.2017.2411
7.
SharmaPRetzMSiefker-RadtkeA, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312-322. doi:10.1016/S1470-2045(17)30065-7
8.
BellmuntJde WitRVaughnDJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015-1026. doi:10.1056/NEJMoa1613683
9.
Challita-EidPMSatpayevDYangP, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76:3003-3013. doi:10.1158/0008-5472.CAN-15-1313
MoherDLiberatiATetzlaffJ, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151:264-269. doi:10.7326/0003-4819-151-4-200908180-00135
12.
RikitakeYMandaiKTakaiY. The role of nectins in different types of cell-cell adhesion. J Cell Sci. 2012;125(pt 16):3713-3722. doi:10.1242/jcs.099572
13.
SamantaDAlmoSC. Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci. 2015;72:645-658. doi:10.1007/s00018-014-1763-4
14.
ZhangYZhangJShenQ, et al. High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett. 2018;15:8789-8795. doi:10.3892/ol.2018.8365
15.
LattanzioRGhasemiRBrancatiF, et al. Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal–A early breast cancer. Oncogenesis. 2014;3:e118. doi:10.1038/oncsis.2014.32
16.
TakanoAIshikawaNNishinoR, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69:6694-6703. doi:10.1158/0008-5472.CAN-09-0016
17.
PavlovaNNPallaschCEliaAE, et al. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2013;2: e00358. doi:10.7554/eLife.00358
18.
BoylanKLBuchananPCManionRD, et al. The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate. Oncotarget. 2017;8:9717-9738. doi:10.18632/oncotarget.14206
19.
NishiwadaSShoMYasudaS, et al. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res. 2015;34:30. doi:10.1186/s13046-015-0144-7
20.
MadernaALeverettCA. Recent advances in the development of new auristatins: structural modifications and applications in antibody drug conjugates. Mol Pharm. 2015;12:1798-1812. doi:10.1021/mp500762u
21.
PitotHCMcElroyEAJrReidJM, et al. Phase I trial of dolastatin10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 1999;5:525-531.
22.
MaddenTTranHBeckD, et al. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 2000;6:1293-1301.
23.
PatelSKeohanMLSaifMW, et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer. 2006;107:2881-2887. doi:10.1002/cncr.22334
24.
ShnyderSDCooperPAMillingtonNJPettiGRBibbyMC. Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. Int J Oncol. 2007;31:353-360.
25.
DoroninaSOTokiBETorgovMY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778-784. doi:10.1038/nbt832
HanThZhaoB. Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos. 2014;42:1914-1920. doi:10.1124/dmd.114.058586
29.
RosenbergJSridharSSZhangJ, et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38:1041-1049. doi:10.1200/JCO.19.02044
30.
RosenbergJEO’DonnellPHBalarAV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37:2592-2600. doi:10.1200/JCO.19.01140
31.
RosenbergJEFlaigTWFriedlanderTW, et al. Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma [abstract]. J Clin Oncol. 2020;20;38(6, suppl):441.
32.
YounesAGopalAKSmithSE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183-2189. doi:10.1200/JCO.2011.38.0410
33.
BanerjeeSOzaAMBirrerMJ, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018;29:917-923. doi:10.1093/annonc/mdy023
34.
McGregorBAO’DonnellPHBalarA, et al. Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): data from EV-201 cohort 1. Ann Oncol. 2019;30(suppl 5):v356-v402.
35.
AaronsonNKAhmedzaiSBergmanB, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376. doi:10.1093/jnci/85.5.365
36.
RabinRde CharroF. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343. doi:10.3109/07853890109002087
LoriotYNecchiAParkSH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338-348. doi:10.1056/NEJMoa1817323
